# Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC

Source: https://onco.cc/trials/nct05491525/  
OnCo record `nct05491525` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial of Vibegron in childhood cancers, run by Urovant Sciences GmbH, now recruiting.

## Summary

Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC is a phase 2/3 interventional study registered as NCT05491525 by Urovant Sciences GmbH, with 71 participants planned, started 2022-10-12 and due to reach its primary completion in 2030-03. Interventions recorded: Vibegron.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05491525
- Phase: 2/3
- Setting: A Phase 2/3, Open-label, Baseline-controlled, Multicenter, Long-term Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With Neurogenic Detrusor Overactivity (NDO) on Clean Intermittent Catheterization (CIC)
- Sponsor: Urovant Sciences GmbH
- Enrolled: 71

## Sources

- ClinicalTrials.gov NCT05491525: https://clinicaltrials.gov/study/NCT05491525

## Connected records

- cancers: [Childhood cancers (all types)](https://onco.cc/cancers/childhood-cancers/)

---
JSON: https://onco.cc/api/v1/entities/nct05491525.json